The World Orphan Drug Congress is entering into its 7th year in November 2016.
The Congress was one of the first events to bring together the full range of stakeholders and influencers in the orphan drug and rare disease sector, from the pharma and biotechs to patient advocates and representatives from payers.
It continues to be a key meeting for the sector in pushing forward with strategy, advocacy and partnering within the rare disease space.
Building on a greatly successful event in 2015, we will be putting together a hard-hitting agenda in 2016.
We will continue to cover the issues that affect the full audience, including pricing and reimbursement, commercialisation, and improving on collaboration, as well as researching the newest areas to ensure the focussed content really reflects the future of the sector.
We will also be working hard to increase the number of representatives present from the HTA, payer and public health arenas, as it is so important to have their input throughout the discussions onsite. Additionally, we will be inviting more members of the patient advocacy community.
We believe these improvements to the programme will fulfil our aim to see 450+ attendees in 2016.